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Abstract
Several studies investigated the possible association between anticholinergic
drugs and diverse clinical outcomes in older persons, but the results are incon-
sistent. The aim of this study was to investigate whether anticholinergic drug
exposure is associated with delirium on admission, length of hospital stay, post-
discharge institutionalization and in-hospital mortality in acutely ill hospitalized
older patients. In this observational chart review study, we included acutely ill
patients aged 65 and older who were admitted to the geriatric ward of the Eras-
mus University Medical Center, Rotterdam, The Netherlands, between 2012
and 2015 (n = 905). Anticholinergic drug exposure on admission was defined
as the use of anticholinergic drugs, total number of anticholinergic drugs and
anticholinergic drug burden score (ADB), quantified with the Anticholinergic
Risk Scale (ARS), the Anticholinergic Cognitive Burden scale (ACB) and the list
of Chew et al. (Chew). Logistic regression analyses were performed to investi-
gate possible associations between anticholinergic drug exposure and the afore-
mentioned outcomes. Analyses were adjusted for age, sex, comorbidities, non-
anticholinergic drugs and delirium, where appropriate. Moderate and high ADB
measured with the ARS were associated with delirium on admission with odds
ratios (OR) of 1.70 (95% confidence interval (CI) = 1.16–2.49) and 1.83 (95%
CI = 1.06–3.15), respectively. High ADB measured with the ARS was also asso-
ciated with postdischarge institutionalization (OR = 2.43, 95% CI = 1.24–4.75).
No associations were found using the ACB and Chew. Future studies are
warranted to investigate the clinical usefulness of the ARS in reducing
complications in older persons.
Abbreviations
ACB, anticholinergic cognitive burden scale; ADB, anticholinergic drug burden;
ARS, anticholinergic risk scale; CCI, charlson comorbidity index; Chew, list of
Chew et al.; eGFR, estimated glomerular filtration rate; GEE, generalized estimating
equations; LOS, length of hospital stay.
Introduction
Drugs with anticholinergic properties are commonly
prescribed in older persons (Collamati et al. 2016).
These drugs are associated with a wide spectrum
of adverse effects including dizziness, blurred vision,
urinary retention, constipation, confusion and possi-
bly also delirium (Collamati et al. 2016). Older persons
are more susceptible to those adverse effects due to an
age-related increase in blood-brain barrier permeability,
a reduction in hepatic and renal clearance and a
decrease in cholinergic neurons and receptors
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(Collamati et al. 2016; Zeevi et al. 2010; Mangoni and
Jackson 2004).
It has been hypothesized that adverse effects of anti-
cholinergic drugs can restrict older persons in performing
daily activities and lead to hospitalizations, longer length
of hospital stay (LOS) and even death (e.g., due to falls).
Additionally, a decline in the ability to perform daily
activities may increase the need for institutionalization in
older persons (Fried et al. 2001). Several studies have
investigated the possible association between anticholiner-
gic drugs and delirium, LOS, physical function and mor-
tality, but the results are inconsistent (Fox et al. 2014;
Ruxton et al. 2015; Pasina et al. 2013; Lowry et al. 2012;
Mangoni et al. 2016). This discrepancy might be caused
by the methods used to assess anticholinergic drug use,
which differ substantially between studies (Ruxton et al.
2015). In some studies, anticholinergic drug use is
assessed with crude measures such as ‘exposed or not
exposed’ and the total number of anticholinergic drugs
taken by a person, whereas in other studies the specific
anticholinergic load of the different drugs is taken into
account. However, little is known about potential differ-
ences in results between these methods and whether the
results can be compared. To the best of our knowledge
no previous study has investigated the association
between anticholinergic drugs and postdischarge institu-
tionalization in acutely ill older patients.
The aim of the study was to investigate whether anti-
cholinergic drug exposure on admission quantified
according to three anticholinergic drug scales is associated
with delirium on admission, LOS, postdischarge institu-
tionalization and in-hospital mortality in acutely ill older
patients admitted to a geriatric ward.
Materials and Methods
In this observational chart review study, we included
acutely ill patients aged 65 and older who were admitted
to the ward of geriatrics of the Erasmus University Medi-
cal Center, Rotterdam, The Netherlands, between 1 Jan-
uary 2012 and 31 December 2015. Patients were excluded
if they were hospitalized for less than 3 days or if data
regarding drug use or outcome measures were not avail-
able. Individual persons could be included more than
once as patient in the study. The study was conducted
according to the principles expressed in the Declaration
of Helsinki.
Demographic and clinical variables
All data were collected from the medical records and
included age, sex, the estimated glomerular filtration rate
(eGFR) on admission, drug use at the time of admission
and the severity of comorbidities calculated with the
Charlson Comorbidity Index (CCI) (Charlson et al.
1987). The CCI encompasses 19 medical conditions
weighted with a score of 1–6, with total scores ranging
from 0 to 37, with higher scores indicating a more severe
burden of comorbidities. Data collected to determine out-
come measures were: delirium status during the hospital
stay, dates of admission and discharge, place of residence
before and after discharge and in-hospital mortality.
Anticholinergic drug exposure
Dispensing records from the community pharmacy were
preferentially used for recording all drugs in use by a
patient at the time of admission. If this information was
not available, we used correspondence letters of general
practitioners or other referrers, or the medication history
taken in the hospital. This information was additionally
combined with patients’ self-reports on over-the-counter
drugs (reported in the medical record). When a drug was
stopped 1 or more days prior to admission, we assessed
whether there was a possibility that the drug was still pre-
sent in a patient’s body at the time of admission by calcu-
lating a time window of 5x the elimination half-life of the
drug.
Several anticholinergic drug scales have been developed
previously that classify drugs according to their anti-
cholinergic activity into four or five categories, ranging
from no anticholinergic activity (score 0) to strong anti-
cholinergic activity (score 3 or 4) (Salahudeen et al.
2015). Three of them, the Anticholinergic Risk Scale
(ARS) (Rudolph et al. 2008), the updated version of the
Anticholinergic Cognitive Burden (ACB) scale (Campbell
et al. 2013) and the list of Chew et al. (2008) (hereafter
called Chew), were used in the present study. Shortly, on
the ARS, drugs are ranked based on their potential to
cause central and peripheral anticholinergic adverse effects
(score range: 0–3). Drugs assigned a score of 1 have a
moderate anticholinergic potential and drugs with scores
2 and 3 have a strong and very strong potential, respec-
tively. On the ACB, drugs are ranked based on their
potential to have a negative effect on cognition (score
range: 0–3). Drugs with a score of 1 are those with serum
anticholinergic activity or in vitro affinity to muscarinic
receptors, but without known clinically relevant cognitive
effects. Drugs with established and clinically relevant cog-
nitive anticholinergic effects were assigned a score of 2 or
3 (Boustani et al. 2008; Campbell et al. 2013). On the
Chew, drugs are ranked based on in vitro serum anti-
cholinergic activity measurements (score range: 0–3).
Drugs with a score of 0.5 have an estimated anticholiner-
gic activity of 0 at therapeutic doses, but may demon-
strate some anticholinergic activity at higher doses. Drugs
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with a score of 1–3 demonstrate low to high anticholiner-
gic activity across the therapeutic range (Chew et al.
2008).
In the present study, anticholinergic drug exposure on
admission was defined as the use of drugs with anti-
cholinergic properties, total number of anticholinergic
drugs and total anticholinergic drug burden score (ADB),
all quantified with the three anticholinergic drug scales.
The ADB is the sum of scores assigned to each drug a
patient is taking.
Outcome measures
The outcomes of interest were delirium on admission,
LOS, postdischarge institutionalization and in-hospital
mortality. On the ward of geriatrics, the diagnosis of
delirium is made by geriatricians as part of daily clinical
practice, according to the criteria of the Diagnostic and
Statistical Manual of Mental Disorders, 4th and 5th edi-
tion (American Psychiatric Association 2000, 2013) and is
based on daily psychiatric examination, medical and nurs-
ing notes, the Delirium Observation Screening scale
scores, and information given by the patient’s closest rela-
tive. In this study, reported diagnoses of delirium were
extracted from the medical records. Delirium was defined
as “present on admission” if the diagnosis was made
within the first 2 days of the hospital stay. All other
patients were considered as not having delirium on
admission.
LOS was defined as the number of days a patient was
hospitalized, with the first day of admission as day one.
Patients who died during the hospital stay were not
included in analyses of LOS.
Postdischarge institutionalization was defined as dis-
charge to an institutional care facility rather than dis-
charge to home. Patients who resided in an institutional
care facility before admission and patients who died dur-
ing the hospital stay were not included in analyses regard-
ing postdischarge institutionalization.
In-hospital mortality was recorded; all patients were
included in the analyses.
Statistical analyses
Differences in characteristics between patients with and
without delirium on admission were compared using the
Chi-square test for categorical variables, the Mann–Whit-
ney U-test for non-normally distributed continuous vari-
ables and the Student t-test for normally distributed
continuous variables.
Logistic regression analysis was performed to calculate
odds ratios (OR) and corresponding 95% confidence
intervals (CI) for delirium on admission, LOS,
postdischarge institutionalization and in-hospital mortal-
ity (dependent variables) according to different measures
of anticholinergic drug exposure (exposure no/yes, total
number of anticholinergic drugs and categories of ADB
quantified with the ARS, the ACB and the Chew). LOS
was divided into two groups based on the median value
found in the overall sample (8.0 days). Number of anti-
cholinergic drugs was treated as a continuous variable.
ADB was divided into three categories: no ADB (for all
scales score 0), moderate ADB (ARS and ACB score 1–2;
Chew score 0.5–1.0) and high ADB (ARS and ACB
score ≥ 3; Chew score ≥ 1.5); the first category was used
as reference. All analyses were adjusted for age, sex, CCI
and number of non-anticholinergic drugs. Analyses of
LOS, postdischarge institutionalization and in-hospital
mortality were additionally adjusted for delirium at any
time during the hospital stay. Subsequently, analyses of
LOS, postdischarge institutionalization and in-hospital
mortality were repeated in the group of patients with
delirium on admission. Considering the suggested cholin-
ergic deficiency in delirium (Hshieh et al. 2008) and the
high prevalence of prolonged LOS, postdischarge institu-
tionalization and in-hospital mortality in patients with
delirium (Witlox et al. 2010; Siddiqi et al. 2006), we
hypothesized that the effect of anticholinergic drug expo-
sure on aforementioned outcomes would be different in
acutely ill older patients with delirium. LOS was divided
into two groups based on the median value found in this
group (10.0 days). Analyses were adjusted for age, sex,
CCI and number of non-anticholinergic drugs.
Repeated measures logistic regression models were fit-
ted for all outcome measures using the Generalized Esti-
mating Equations (GEE) method, to examine the effect of
multiple inclusions per individual on the calculated esti-
mates. Models were adjusted for the same covariates as
the main analyses.
All statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS), version 21.0 (IBM
Corp., Armonk, NY). Results were considered statistically
significant at a P < 0.05.
Results
A total of 1193 patients were admitted during the study
period, of which 165 did not meet the inclusion criteria.
Of the remaining 1028 patients, 123 were excluded: 119
were hospitalized for less than 3 days and four had
unclear data regarding drug use or outcome measures. In
total, 905 patients were included in the study; 215 of
them (23.8%) had delirium on admission (Fig. 1). No
statistically significant differences were found in sex distri-
bution (men: 48.3% versus 41.5%, P = 0.155) and mean
age (81.0  7.0 versus 81.0  7.5, P = 0.966) between
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patients who were included and those who were not.
Baseline and discharge characteristics of the included
patients are outlined in Table 1.
Delirium and length of stay
Table 2 presents the ORs and corresponding 95% CIs for
delirium on admission and LOS ≥ 9 days according to
different measures of anticholinergic drug exposure.
After adjustment for age, sex, CCI and number of non-
anticholinergic drugs, we found that exposure to anti-
cholinergic drugs according to the ARS was associated
with an increased odds of having delirium on admission
(OR = 1.73, 95% CI = 1.23–2.45). Each additional anti-
cholinergic drug used by a patient was associated with a
38% increase in odds of having delirium on admission
(OR = 1.38, 95% CI = 1.10–1.73). Both moderate and
high ADB measured with the ARS were associated with
an increased odds of having delirium on admission when
compared to no ADB (OR = 1.70, 95% CI = 1.16–2.49
and OR = 1.83, 95% CI = 1.06–3.15, respectively). No
associations were found between anticholinergic drug
exposure quantified with the ACB and the Chew, and
delirium.
After adjustment for age, sex, CCI, number of non-
anticholinergic drugs and delirium at any time during the
hospital stay, no associations were found between anti-
cholinergic drug exposure and LOS.
GEE logistic regression models for delirium on admis-
sion and LOS showed that the inclusion of individuals
multiple times did not affect the estimates (data not
shown).
Postdischarge institutionalization and in-
hospital mortality
Table 3 presents the ORs and corresponding 95% CIs for
postdischarge institutionalization and in-hospital mortality
according to different measures of anticholinergic drug expo-
sure. After adjustment for age, sex, CCI, number of non-
anticholinergic drugs and delirium at any time during the
hospital stay, we found that each additional anticholinergic
drug used by a patient according to the ARS was associated
with a 38% increase in odds of being institutionalized after
discharge (OR = 1.38, 95% CI = 1.02–1.86). Additionally, a
high ADB quantified with the ARS was associated with a 2.43
times higher odds of being institutionalized after discharge in
comparison to no ADB (OR = 2.43, 95% CI = 1.24–4.75).
No associations were found between anticholinergic drug
exposure quantified with the ACB and the Chew, and post-
discharge institutionalization.
After adjustment for age, sex, CCI, number of non-
anticholinergic drugs and delirium at any time during the
hospital stay, no associations were found between anti-
cholinergic drug exposure and in-hospital mortality.
GEE logistic regression models for postdischarge insti-
tutionalization and in-hospital mortality showed that the
inclusion of individuals multiple times did not affect the
estimates (data not shown).
Analyses in patients with delirium on
admission
Table 4 presents the ORs and corresponding 95% CIs for
LOS ≥ 11 days, postdischarge institutionalization and in-
hospital mortality according to different measures of anti-
cholinergic drug exposure in patients with delirium on
admission. The association between anticholinergic drug
exposure and postdischarge institutionalization found in
the total group of acutely ill patients was not maintained
in this subgroup. No associations were found between
anticholinergic drug exposure and LOS and in-hospital
mortality.
GEE logistic regression models for the three outcome
measures showed that the inclusion of individuals multi-
ple times did not affect the estimates (data not shown).
Discussion
In this study, we found that anticholinergic drug expo-
sure, measured with the ARS, is associated with an
215
with delirium
on admission
690
without delirium
on admission
1028 patients (807 individuals)
123 patients excluded:
119: hospital stay <3 days (16 died)
3: unclear data regarding drug use
1: unclear data regarding discharge
disposition
905 patients (718 individuals) included
1193 patients (881 individuals) admitted
165 patients excluded:
43: <65 years
122: short medical intervention or   
investigation
Figure 1. Flowchart of study sample selection.
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increased prevalence of delirium and increased postdis-
charge institutionalization in acutely ill hospitalized older
patients.
Our finding that anticholinergic drug exposure mea-
sured with the ARS is associated with delirium, is in
agreement with the results of previous studies performed
in critically ill patients (Wolters et al. 2015), palliative
care patients (Zimmerman et al. 2014), patients with
Parkinson’s disease (Crispo et al. 2016) and older nursing
home residents (Landi et al. 2014). Also, previous studies
found no association between anticholinergic drug expo-
sure, measured with the ACB or the Anticholinergic Drug
Scale, and delirium in older hospitalized patients (Moorey
et al. 2016; Campbell et al. 2011; Wolters et al. 2015).
These findings strengthen the observation that results
may differ depending on which scale is used when assess-
ing anticholinergic drug exposure.
Several studies have investigated the possible relation-
ship between anticholinergic drug exposure and LOS in
older hospitalized persons (Pasina et al. 2013; Kidd et al.
2014; Lowry et al. 2011; Mangoni et al. 2016; Lowry et al.
2012). Three of them used the ARS and/or ACB and
found, in line with our study, no association between
anticholinergic drug exposure and LOS (Kidd et al. 2014;
Pasina et al. 2013; Lowry et al. 2011). Mangoni et al.
(2016) also used the ARS and found that anticholinergic
drug exposure was only associated with prolonged LOS in
older patients who were admitted during a non-heat wave
period. In contrast to our study, the previous study
(Mangoni et al. 2016) included only older patients who
were discharged home and did not exclude patients who
were hospitalized for <3 days. Therefore, it might be
speculated that the patients included in the study of Man-
goni et al. (2016) were healthier and probably less frail
Table 1. Baseline and discharge characteristics of the overall study sample and stratified for delirium on admission.
Characteristic Overall sample n = 905 No delirium n = 690 Delirium n = 215 P-value1
Male, n (%) 437 (48.3) 316 (45.8) 121 (56.3) 0.0072
Age, years, mean  SD 81.0  7.03 80.7  7.1 81.9  6.7 0.0223
Place of residence before admission, n (%) 0.0352
Home (with or without home care) 696 (76.9) 542 (78.6) 154 (71.6)
Institutional care facility 209 (23.1) 148 (21.4) 61 (28.4)
First time on the ward of geriatrics, n (%) 580 (64.1) 426 (61.7) 154 (71.6) 0.0082
CCI, median (IQR) 2.0 (1.0–4.0) 2.0 (1.0–4.0) 3.0 (1.0–4.0) 0.6784
eGFR, mL/min, median (IQR) 54.0 (35.0–75.0) 54.0 (35.0–75.0) 53.0 (36.0–74.0) 0.9184
Number of drugs, median (IQR) 8.0 (6.0–12.0) 8.0 (6.0–12.0) 8.0 (6.0–12.0) 0.9634
Use of at least one DAP, n (%)
ARS 256 (28.3) 180 (26.1) 76 (35.3) 0.0092
ACB 644 (71.2) 488 (70.7) 156 (72.6) 0.6052
Chew 523 (57.8) 399 (57.8) 124 (57.7) 0.9692
Number of DAPs, median (IQR)
ARS 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0114
ACB 1.0 (0.0–2.0) 1.0 (0.0–2.0) 1.0 (0.0–2.0) 0.3834
Chew 1.0 (0.0–1.0) 1.0 (0.0–1.0) 1.0 (0.0–1.0) 0.5854
ADB score, median (IQR)
ARS 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0154
ACB 1.0 (0.0–3.0) 1.0 (0.0–3.0) 1.0 (0.0–3.0) 0.1184
Chew 0.5 (0.0–1.0) 0.5 (0.0–1.0) 0.5 (0.0–1.0) 0.4744
Delirium developed during the hospital stay, n (%) 45 (5.0) 45 (6.5) n/a n/a
Place of residence after discharge, n (%)
Home (with or without home care) 448 (49.5) 389 (56.4) 59 (27.4) <0.0012
Institutional care facility 392 (43.3) 260 (37.7) 132 (61.4)
In-hospital mortality, n (%) 65 (7.2) 41 (5.9) 24 (11.2) 0.0102
Length of stay, days, median (IQR) 8.0 (5.0–11.0) 7.0 (5.0–11.0) 10.0 (7.0–14.0) <0.0014
SD, standard deviation; IQR, interquartile range; CCI, Charlson comorbidity index (range: 0–37); eGFR, estimated Glomerular Filtration Rate; DAP,
drug with anticholinergic properties; ARS, Anticholinergic Risk Scale; ACB, Anticholinergic Cognitive Burden scale; ADB, Anticholinergic Drug
Burden.
1No Delirium versus Delirium
2Chi-square test.
3Student t-test.
4Mann–Whitney U-test.
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than our study population. Lowry et al. (2012) also found
that the use of anticholinergic drugs was associated with
prolonged LOS in older hospitalized persons. However,
they used an alternate anticholinergic drug scale and had
previously found that the ARS was not associated with
LOS in the same study sample (Lowry et al. 2011).
As far as we are aware this is the first study showing an
association between anticholinergic drug exposure, mea-
sured with the ARS, and postdischarge institutionalization
in acutely ill older patients. In a previous study, no asso-
ciation was found between anticholinergic drug use and
nursing home admission within one year after hospital
discharge (Narbey et al. 2013). However, Narbey et al.
(2013) did not use an anticholinergic drug scale and
treatment with anticholinergic drugs can have changed
over time. Therefore, caution is warranted in extrapolat-
ing their results. A possible explanation for our finding
that anticholinergic drug exposure, measured with the
ARS, is associated with postdischarge institutionalization,
might be an underlying decrease in functional perfor-
mance. Several studies have found that anticholinergic
drug exposure quantified with the ARS is associated with
a reduced physical function in older persons (Pasina et al.
2013; Lowry et al. 2011; Landi et al. 2014; Lampela et al.
2013; Koshoedo et al. 2012).
Several studies have investigated the possible associa-
tion between the use of anticholinergic drugs and in-hos-
pital mortality in older patients (Lowry et al. 2011, 2012;
Table 2. Odds ratios for delirium on admission and prolonged length of hospital stay according to different measures of anticholinergic drug
exposure.
Variable
Delirium on admission LOS ≥ 9 days
Delirium/no delirium OR (95% CI)1 LOS ≥ 9/LOS < 9 OR (95% CI)2,3
ARS
Exposure to DAPs
No 139/510 1.00 (ref) 274/330 1.00 (ref)
Yes 76/180 1.73 (1.23–2.45) 114/122 1.06 (0.77–1.48)
Number of DAPs
Per drug 215/690 1.38 (1.10–1.73) 388/452 0.99 (0.79–1.24)
ADB score
0 139/510 1.00 (ref) 274/330 1.00 (ref)
1–2 52/121 1.70 (1.16–2.49) 75/84 1.00 (0.69–1.45)
≥3 24/59 1.83 (1.06–3.15) 39/38 1.23 (0.73–2.07)
ACB
Exposure to DAPs
No 59/202 1.00 (ref) 113/133 1.00 (ref)
Yes 156/488 1.10 (0.77–1.59) 275/319 0.99 (0.71–1.38)
Number of DAPs
Per drug 215/690 1.07 (0.94–1.23) 388/452 0.93 (0.82–1.06)
ADB score
0 59/202 1.00 (ref) 113/133 1.00 (ref)
1–2 91/311 0.99 (0.67–1.46) 170/199 0.98 (0.70–1.39)
≥3 65/177 1.39 (0.89–2.18) 105/120 0.99 (0.66–1.51)
Chew
Exposure to DAPs
No 91/291 1.00 (ref) 161/193 1.00 (ref)
Yes 124/399 1.09 (0.78–1.51) 227/259 1.10 (0.81–1.49)
Number of DAPs
Per drug 215/690 1.11 (0.94–1.31) 388/452 0.95 (0.82–1.12)
ADB score
0 91/291 1.00 (ref) 161/193 1.00 (ref)
0.5–1 82/285 1.00 (0.71–1.43) 161/182 1.11 (0.81–1.54)
≥1.5 42/114 1.34 (0.85–2.11) 66/77 1.05 (0.69–1.62)
Values in bold are statistically significant (P < 0.05).
OR, odds ratio; CI, confidence interval; LOS, length of hospital stay; DAPs, drugs with anticholinergic properties; ARS, Anticholinergic Risk Scale;
ACB, Anticholinergic Cognitive Burden scale; ADB, Anticholinergic Drug Burden.
1Model adjusted for age, sex, Charlson comorbidity index and non-anticholinergic drugs.
2Model adjusted for age, sex, Charlson comorbidity index, non-anticholinergic drugs and delirium at any time during the hospital stay.
3Patients who died during the hospital stay were excluded.
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Mangoni et al. 2016; Kidd et al. 2014). Mangoni et al.
(2016), Kidd et al. (2014) and Lowry et al. (2012) used
the ARS, the ACB and the anticholinergic component of
the Drug Burden Index respectively, and in line with our
study, found no association. In a subgroup of older
patients with hyponatremia, Lowry et al. (2011) reported
that high ARS scores were associated with increased in-
hospital mortality.
To the best of our knowledge, no previous studies
investigated the possible association between anticholiner-
gic drug use and clinical outcomes in acutely ill hospital-
ized older patients with delirium. Recently, Kolanowski
et al. (2015) found that the use of anticholinergic drugs
according to the ACB was associated with prolonged LOS
and reduced physical function, but not with discharge
disposition in older persons with delirium who resided in
a postacute care facility. In contrast to our study, their
sample size was relatively small, all participants had
dementia, were not acutely ill, and in the vast majority
delirium was resolving.
Although no conclusions on causality can be drawn
from this observational study, our results suggest that
older persons who are exposed to anticholinergic drugs
are at increased risk for delirium when they become
acutely ill. Additionally, they might be at increased risk
for postdischarge institutionalization independently of
delirium. The question remains whether anticholinergic
drugs ‘in general’ are associated with delirium and
postdischarge institutionalization, since only the ARS
was associated with them. Discrepancies in results
Table 3. Odds ratios for postdischarge institutionalization and in-hospital mortality according to different measures of anticholinergic drug
exposure.
Variable
Postdischarge institutionalization In-hospital mortality
Institutionalized/home OR (95% CI)1,2 Dead/alive OR (95% CI)1
ARS
Exposure to DAPs
No 151/333 1.00 (ref) 45/604 1.00 (ref)
Yes 63/110 1.43 (0.95–2.14) 20/236 1.20 (0.67–2.15)
Number of DAPs
Per drug 214/443 1.38 (1.02–1.86) 65/840 1.07 (0.73–1.58)
ADB score
0 151/333 1.00 (ref) 45/604 1.00 (ref)
1–2 40/81 1.17 (0.74–1.85) 14/159 1.20 (0.63–2.29)
≥3 23/29 2.43 (1.24–4.75) 6/77 1.22 (0.47–3.13)
ACB
Exposure to DAPs
No 72/129 1.00 (ref) 15/246 1.00 (ref)
Yes 142/314 0.84 (0.56–1.25) 50/594 1.51 (0.80–2.84)
Number of DAPs
Per drug 214/443 0.94 (0.80–1.11) 65/840 1.13 (0.90–1.41)
ADB score
0 72/129 1.00 (ref) 15/246 1.00 (ref)
1–2 85/207 0.73 (0.48–1.12) 33/369 1.52 (0.79–2.93)
≥3 57/107 1.12 (0.68–1.86) 17/225 1.47 (0.66–3.25)
Chew
Exposure to DAPs
No 99/202 1.00 (ref) 28/354 1.00 (ref)
Yes 115/241 1.15 (0.80–1.67) 37/486 1.11 (0.64–1.91)
Number of DAPs
Per drug 214/443 1.05 (0.85–1.29) 65/840 1.11 (0.84–1.46)
ADB score
0 99/202 1.00 (ref) 28/354 1.00 (ref)
0.5–1 81/178 1.09 (0.74–1.62) 24/343 1.01 (0.56–1.83)
≥1.5 34/63 1.37 (0.80–2.36) 13/143 1.39 (0.66–2.92)
Values in bold are statistically significant (P < 0.05).
OR, odds ratio; CI, confidence interval; DAPs, drugs with anticholinergic properties; ARS, anticholinergic risk scale; ACB, anticholinergic cognitive
burden scale; ADB, anticholinergic drug burden.
1Model adjusted for age, sex, Charlson comorbidity index, non-anticholinergic drugs and delirium at any time during the hospital stay.
2Patients who resided in an institutional care facility before admission and patients who died during the hospital stay were excluded.
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between the ARS, ACB and Chew might be related to
the large variation in number and ranking of drugs
within each scale, which is caused by the different
methods used to develop them. In all anticholinergic
drug scales, the calculation of the ADB is based on the
assumption that anticholinergic effects of different drugs
are additive in a linear fashion. This might not be the
case and therefore, inclusion of drugs without known
clinically relevant anticholinergic effects might dilute
possible associations. Therefore, it might be warranted
to identify only drugs with established peripheral and
cognitive anticholinergic effects in future studies. Fur-
thermore, it might be possible that in delirium not
only central anticholinergic effects may play a role, if
any, but also peripheral anticholinergic effects. Blurred
vision, urinary retention, constipation and confusion
are risk factors for delirium and might explain why the
ARS was associated with delirium. However, since we
did not collect data on adverse effects, this remains
speculative. In patients with delirium we found that the
ARS was not associated with postdischarge institutional-
ization. It might be possible that the sample size was
too small; other explanations could be that anticholin-
ergic drugs play a minor role, if any, in the clinical
course of delirium, or that anticholinergic drugs were
stopped more frequently after admission since a cholin-
ergic deficiency is still one of the most hypothesized
causes of delirium (Hshieh et al. 2008).
Table 4. Odds ratios for prolonged length of hospital stay, postdischarge institutionalization and in-hospital mortality according to different mea-
sures of anticholinergic drug exposure in patients with delirium on admission.
Variable
LOS ≥ 11 days Postdischarge institutionalization In-hospital mortality
LOS ≥ 11/LOS < 11 OR (95% CI)1,2
Institutionalized/
home OR (95% CI)1,3 Dead/alive OR (95% CI)1
ARS
Exposure to DAPs
No 58/67 1.00 (ref) 55/43 1.00 (ref) 14/125 1.00 (ref)
Yes 30/36 1.07 (0.57–2.00) 28/15 1.57 (0.72–3.45) 10/66 2.08 (0.79–5.50)
Number of DAPs
Per drug 88/103 1.00 (0.68–1.49) 83/58 1.36 (0.74–2.50) 24/191 1.17 (0.64–2.14)
ADB score
0 58/67 1.00 (ref) 55/43 1.00 (ref) 14/125 1.00 (ref)
1-2 20/24 1.02 (0.51–2.07) 18/11 1.40 (0.58–3.39) 8/44 2.52 (0.90–7.08)
≥3 10/12 1.18 (0.44–3.12) 10/4 2.08 (0.56–7.63) 2/22 1.15 (0.21–6.33)
ACB
Exposure to DAPs
No 26/29 1.00 (ref) 28/18 1.00 (ref) 4/55 1.00 (ref)
yes 62/74 0.99 (0.51–1.91) 55/40 0.85 (0.39–1.84) 20/136 2.19 (0.66–7.25)
Number of DAPs
Per drug 88/103 0.79 (0.61–1.03) 83/58 0.75 (0.54–1.04) 24/191 1.22 (0.82–1.84)
ADB score
0 26/29 1.00 (ref) 28/18 1.00 (ref) 4/55 1.00 (ref)
1-2 38/41 1.05 (0.52–2.12) 32/26 0.75 (0.33–1.70) 12/79 1.94 (0.55–6.77)
≥3 24/33 0.88 (0.39–1.99) 23/14 1.12 (0.42–3.03) 8/57 2.99 (0.72–12.51)
Chew
Exposure to DAPs
No 39/43 1.00 (ref) 41/28 1.00 (ref) 9/82 1.00 (ref)
Yes 49/60 0.98 (0.53–1.79) 42/30 1.07 (0.52–2.19) 15/109 1.64 (0.62–4.33)
Number of DAPs
Per drug 88/103 0.92 (0.67–1.26) 83/58 1.05 (0.72–1.55) 24/191 1.47 (0.92–2.35)
ADB score
0 39/43 1.00 (ref) 41/28 1.00 (ref) 9/82 1.00 (ref)
0.5-1 34/39 1.01 (0.52–1.95) 27/23 0.91 (0.42–1.98) 9/73 1.30 (0.45–3.77)
≥1.5 15/21 0.90 (0.39–2.08) 15/7 1.61 (0.55–4.72) 6/36 2.82 (0.80–9.95)
OR, odds ratio; CI, confidence interval; LOS, length of hospital stay; DAPs, drugs with anticholinergic properties; ARS, anticholinergic risk scale;
ACB, anticholinergic cognitive burden scale; ADB, anticholinergic drug burden.
1Model adjusted for age, sex, Charlson comorbidity index and non-anticholinergic drugs.
2Patients who died during the hospital stay were excluded.
3Patients who resided in an institutional care facility before admission and patients who died during the hospital stay were excluded.
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Limitations and strengths
This study has some limitations. First, the study design
limits the ability to identify causal associations between the
use of anticholinergic drugs and the outcome measures.
Information on any changes in drug exposure during hos-
pitalization was not collected and we cannot exclude that
the treatment approach for the acute illness has influenced
our results. Moreover, other health-related factors, such as
the reason for admission, the severity of illness, functional
status and the degree of cognitive functioning can have
influenced our results. In this study we were not able to
score and adjust for the severity of illness and physical
function, since information on those items was not always
available. However, we have adjusted for the CCI in statis-
tical models; therefore, we believe that we have provided
an indirect adjustment for dementia. A comorbid cognitive
disturbance, not diagnosed as dementia (yet), can still be
a confounding factor. Second, the three anticholinergic
drug scales were developed several years ago (the ARS and
the Chew in 2008; the ACB was last updated in 2012)
and do not include newer anticholinergic drugs. This
might have led to an underestimation of the anticholiner-
gic drug exposure, but we believe that our results are only
minimally influenced by this. Third, the three anticholiner-
gic drug scales do not take into account daily drug dose
and treatment duration. Since it is likely that anticholiner-
gic effects will be amplified with higher drug doses and
longer treatment duration, this could have influenced our
results. Fourth, our results are mainly based on informa-
tion on prescribed drugs; minimal information was avail-
able on treatment adherence prior to hospitalization.
The study has several strengths. First, the findings were
obtained in a relatively large sample size. Second, we used
three anticholinergic drug scales within the same popula-
tion which makes it possible to make clear comparisons
between results. Third, the ARS, ACB and Chew provide
a quick and simple measure of anticholinergic drug
burden and are suitable for clinical practice.
Conclusion
In this study, we found that anticholinergic drug exposure
measured with the ARS, is associated with an increased
prevalence of delirium on admission and increased post-
discharge institutionalization in acutely ill hospitalized
older patients.
Considering the fact that delirium and postdischarge
institutionalization are associated with a very poor prog-
nosis, future studies are needed to investigate whether
regular medication reviews using the ARS are a useful
tool in order to reduce complications and to preserve
independent functioning in older persons.
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